EUROCONDOR
European Consortium for the Early Treatment of Diabetic Retinopathy
| Coordinatore | FUNDACIO INSTITUT DE RECERCA DE L'HOSPITAL UNIVERSITARI VALL D'HEBRON
Organization address
address: Passeig Vall d'Hebron contact info |
| Nazionalità Coordinatore | Spain [ES] |
| Sito del progetto | http://eurocondor.eu/ |
| Totale costo | 7˙755˙341 € |
| EC contributo | 5˙998˙762 € |
| Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
| Code Call | FP7-HEALTH-2011-two-stage |
| Funding Scheme | CP-FP |
| Anno di inizio | 2012 |
| Periodo (anno-mese-giorno) | 2012-03-01 - 2016-02-29 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
FUNDACIO INSTITUT DE RECERCA DE L'HOSPITAL UNIVERSITARI VALL D'HEBRON
Organization address
address: Passeig Vall d'Hebron contact info |
ES (BARCELONA) | coordinator | 936˙725.30 |
| 2 |
AIBILI ASSOCIACAO PARA INVESTIGACAO BIOMEDICA E INNOVACAO EM LUZ E IMAGEM
Organization address
address: "Azinhaga de Santa Comba, Celas" contact info |
PT (COIMBRA) | participant | 958˙425.40 |
| 3 |
BCN PEPTIDES S.A
Organization address
address: "Carretera Comarcal c-244, km. 22, Pol. Ind. Els Vinyets-Els Fogars, Sector 2" contact info |
ES (Barcelona) | participant | 811˙892.20 |
| 4 |
INSTITUT CATALA DE LA SALUT
Organization address
address: GRAN VIA DE LES CORTS CATALANES 587 contact info |
ES (BARCELONA) | participant | 330˙601.84 |
| 5 |
GLOUCESTERSHIRE HOSPITALS NHS FOUNDATION TRUST
Organization address
address: COLLEGE LAWN 1 contact info |
UK (CHELTENHAM) | participant | 325˙601.84 |
| 6 |
SYDDANSK UNIVERSITET
Organization address
address: CAMPUSVEJ 55 contact info |
DK (ODENSE M) | participant | 317˙239.38 |
| 7 |
UNIVERSITA VITA-SALUTE SAN RAFFAELE
Organization address
address: Via Olgettina 58 contact info |
IT (MILANO) | participant | 287˙238.62 |
| 8 |
ASTON UNIVERSITY
Organization address
address: ASTON TRIANGLE contact info |
UK (BIRMINGHAM) | participant | 280˙601.84 |
| 9 |
UNIVERSITA DEGLI STUDI DI PADOVA
Organization address
address: VIA 8 FEBBRAIO 2 contact info |
IT (PADOVA) | participant | 270˙601.84 |
| 10 |
UNIVERSITAET ULM
Organization address
address: HELMHOLTZSTRASSE 16 contact info |
DE (ULM) | participant | 255˙601.83 |
| 11 |
THE UNIVERSITY OF LIVERPOOL
Organization address
address: Brownlow Hill, Foundation Building 765 contact info |
UK (LIVERPOOL) | participant | 227˙238.62 |
| 12 |
MOORFIELDS EYE HOSPITAL NHS FOUNDATION TRUST
Organization address
address: City Road 162 contact info |
UK (LONDON) | participant | 195˙601.83 |
| 13 |
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS
Organization address
address: 3 Avenue Victoria contact info |
FR (PARIS) | participant | 180˙601.83 |
| 14 |
UNIVERSITA DEGLI STUDI DI TORINO
Organization address
address: Via Giuseppe Verdi 8 contact info |
IT (TORINO) | participant | 156˙400.00 |
| 15 |
FEDERATION INTERNATIONALE DU DIABETE REGION EUROPE AISBL
Organization address
address: CHAUSSEE DE LA HULPE 166 BLOC C contact info |
BE (BRUXELLES) | participant | 156˙000.00 |
| 16 |
AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS
Organization address
address: CALLE SERRANO 117 contact info |
ES (MADRID) | participant | 109˙900.00 |
| 17 |
FUNDACION DE LA COMUNIDAD VALENCIANA CENTRO DE INVESTIGACION PRINCIPE FELIPE
Organization address
address: CALLE EDUARDO PRIMO YUFERA 3 contact info |
ES (VALENCIA) | participant | 109˙900.00 |
| 18 |
CONSORCIO DE APOYO A LA INVESTIGACION BIOMEDICA EN RED
Organization address
address: CALLE SINESIO DELGADO 6 contact info |
ES (MADRID) | participant | 88˙589.70 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'Diabetic retinopathy (DR), the leading cause of blindness among working-age individuals in developed countries has been classically considered to be a microcirculatory disease of the retina. However, there is growing evidence to suggest that retinal neurodegeneration is an early event in the pathogenesis of DR. For this reason, it is reasonable to hypothesize that therapeutic strategies based on neuroprotection will be effective not only in preventing or arresting retinal neurodegeneration but also in preventing the development and progression of the early stages of DR (ie. microaneurysms and/or retinal thickness). EUROCONDOR (European Consortium for the Early Treatment of Diabetic Retinopathy) is a solid and well balanced consortium (ophthalmologists, endocrinologists, basic researchers) which has been created in order to implement the first clinical trial using eye drops for treatment of the early stages of DR. The participants are top leaders in their field and central readings will be performed by the Coordinating Centre of the European Vision Institute Clinical Research Network (EVICR.Net). The main objectives of the project are the following: Primary objective: To assess whether the selected neuroprotective drugs (brimonidine and somatostatin) administered topically are able to prevent or arrest neurodegeneration, as well as the development and progression of the early stages of DR. Secondary objectives: 1) To determine the prevalence of functional abnormalities related to neurodegeneration in those patients without or with minimal microvascular damage under ophthalmoscopic examination. 2) To compare the effectiveness of the selected drugs. 3) To evaluate the local and systemic adverse effects of the selected drugs. 4) To identify those patients most prone to progressive worsening (characterization of phenotypes and circulating biomarkers). 5) To determine the molecular mechanisms by which the selected drugs exert their beneficial effects.'